Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1NSCLC 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1

Interventions

pegaspargase 5tislelizumab 2selinexor 2fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Busulfan 2Azacitidine 2Asparaginase 2sugemalimab 1relatlimab 1pembrolizumab 1gemcitabine-oxaliplatin regimen 1fludarabine 1Vorinostat 1Valganciclovir 1Transplantation 1Tomography, X-Ray Computed 1Thiotepa 1Therapeutics 1Sirolimus 1Positron-Emission Tomography 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × sugemalimab × 1 year × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡